Gross margin benefited from the outperformance of high margin Specialty Medicines, pricing benefits and the annualization ... to the resolution of the Zantac litigation. Next slide, please.

Notably, GSK’s previously sold antacid Zantac may have caused cancer in some ... Sciences focuses on oligonucleotide technology that uses synthetic DNA or RNA to produce genetic treatments ...

Proton pump inhibitors (PPIs) are widely used medications to manage common digestive issues like heartburn, acid reflux, and ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... representing largely average uses of capital. The asset swap appears to be ...

GSK has also reached an agreement to pay $70 million to resolve the Zantac Qui Tam suit previously filed by Valisure. The arrangement is awaiting final approval from the Department of Justice.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead. Just over a week ago, Judge Vivian ...